Estrogen therapy is associated with reduced risk of coronary artery disease in postmenopausal women. The atheroprotective effects of estrogen may in part be due to favorable changes in lipids, but other biological effects may also be important. Cytomegalovirus, a potential atherogenic agent, causes rapid increases in intracellular reactive oxygen species which are essential for transcription factor (NFkappaB) activation. NFkappaB in turn activates the major immediate early promotor (MIEP), with subsequent expression of the major immediate early protein product IE-72 which transactivates the MIEP, all critical events for viral replication. Because estrogen and the anti-estrogen tamoxifen have antioxidant properties, we examined the effect of estrogen and tamoxifen on generation of reactive oxygen species using an intracellular fluorescent marker (dichlorofluorescein), and on the early intracellular events following cytomegalovirus infection of human coronary smooth muscle cells. We found that 17beta-estradiol at physiological concentrations (0.1- 0.5 nM) dose-dependently inhibited cytomegalovirus-induced reactive oxygen species accumulation, as did tamoxifen at therapeutic concentrations (5-500 nM); progesterone (2.5- 25 nM) was ineffective. To determine the relevance of this finding, we next co-transfected smooth muscle cells with a reporter gene under the control of the MIEP, and with an IE-72 expression vector. IE-72 stimulated MIEP transcriptional activity 2-3 fold, an effect inhibited by estrogen and by tamoxifen. Estrogen or tamoxifen, but not progesterone, lowered viral titers and reduced cytopathic effects (plaque formation) by 50% at 8 days after cytomegalovirus infection. We conclude that estrogen and tamoxifen have anti-cytomegalovirus effects by inhibiting reactive oxygen species generation following infection of coronary smooth muscle cells. To the extent that cytomegalovirus is a risk factor for atherosclerosis, this antioxidant effect may contribute to the anti-atherogenic effect of hormone therapy. We further demonstrated that pretreatment with estradiol inhibits expression of intercellular adhesion molecule-1 (ICAM-1) mRNA and protein (both are induced by viral infection); 3-methoxyestrone treatment was ineffective. We also found that infected smooth muscle cells release TNFalpha into the supernatant, and pretreatment with estradiol attenuated TNFalpha release. These anti-inflammatory properties of 17beta-estradiol are shared by the stereoisoner 17alpha-estradiol, which in contrast to 17beta-estradiol has only weak affinity for the estrogen receptor, suggesting non-receptor dependent mechanisms. Updated 9/15/1999 as follows: We detected ICAM-1 mRNA at 3 hours to 24 hours after CMV infection, by performing Northern blot analysis of ICAM-1 in lysates from CMV-infected or uninfected human coronary smooth muscle cells (SMC). ICAM mRNA was not detectable in uninfected cells, but was induced at 3 hours after infection. We have previously shown that infected SMC express HCMV-immediate early protein IE72, a potent transcription factor, at about 3 hours after infection, we asked whether IE72 could induce ICAM-1. The ICAM-1 promoter contains essential NF-kappaB binding sites, and IE72-transactivational activity is dependent on NF-kappaB. We therefore co-transfected SMC with the ICAM-1-CAT (-277/+1) reporter (1 essential NF-kappaB site) and with an IE72 expression vector. We show that IE72 transfection (0.01, 0.05, 0.1 ug) dose-dependently activates the ICAM promoter. We further detected ICAM-1 mRNA at 6 hours after infection; at this point after infection, SMC express viral IE84, another promiscuous transcription factor, which unlike IE72, is not dependent on NF-kappaB. We then demonstrated dose- dependent transactivation of ICAM-1-CAT by IE84 (0.01, 0.05, 0.1 ug) by cotransfecting SMC with ICAM-CAT and IE84. Under the conditions employed in these experiments, cotransfection of SMC with both IE72 and IE84 did not yield additive or synergistic transcriptional effects. We conclude that induction of ICAM-1 mRNA and protein in infected SMC is due, at least partly, to transcriptional activation by HCMV immediate early proteins IE72 and/or IE84. - estrogen, tamoxifen, HCMV, major immediate early promoter (MIEP), HCMV-proteins IE72 and IE84, transcription, SMC, ICAM-1

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Intramural Research (Z01)
Project #
1Z01HL005000-03
Application #
6290451
Study Section
Cell Biology Integrated Review Group (CB)
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Heart, Lung, and Blood Institute
Department
Type
DUNS #
City
State
Country
United States
Zip Code